Humacyte Secures $150,000,000 Series B Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=fde22cf5-50de-4485-a2ae-2ce919adb28d - Date
10/20/2015 - Company Name
Humacyte - Mailing Address
7020 Kit Creek Rd. Morrisville, NC 27560 USA - Company Description
Humacyte’s core technology is the engineering of human-based tissue scaffolds that can be shaped into tubes, sheets, or particulate conformations and can be applied to many specific applications. - Website
http://www.humacyte.com - Transaction Type
Venture Equity - Transaction Amount
$150,000,000 - Transaction Round
Series B - Proceeds Purposes
The funding will support the upcoming global Phase III clinical trials of Humacyte’s investigational human acellular vessel (HAV), HUMACYL, currently being developed to provide vascular access for patients with End Stage Renal Disease (ESRD) who require hemodialysis, a process of cleansing blood for patients whose kidneys no longer function adequately. Funding will also support the development of future pipeline products with the potential to improve treatment outcomes for patients with a variety of vascular and non-vascular diseases, such as Coronary Artery Bypass, Replacement Trachea and Esophagus, and bypass for Peripheral Arterial Disease. - M&A Terms
- Venture Investor
Access Industries - Venture Investor
Investor - Venture Investor
Investor
